


Image
In re Patent Application of

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty Dkt. 620-190
C# M#

Image
1623

SCHNEIDER et al



TC/A.U.

Serial No. 10/088,677

Examiner:

Filed: May 31, 2002

Date: March 22, 2004

Title: USE OF REPLICATION-DEFICIENT ADENOVIRAL VECTOR TO BOOST CD8+T
CELL IMMUNE RESPONSE TO ANTIGEN

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Correspondence Address Indication Form Attached.

Fees are attached as calculated below:

Total effective claims after amendment previously paid for	0 20	minus highest number (at least 20) =	0 0	x x	\$ 18.00 \$ 86.00	\$ 0.00	\$ 0.00
Independent claims after amendment previously paid for	0 3	minus highest number (at least 3) =	0 0	x x	\$ 18.00 \$ 86.00	\$ 0.00	\$ 0.00
If proper multiple dependent claims now added for first time, add \$290.00 (ignore improper)						\$ 0.00	\$ 0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$420.00/2 months; \$950.00/3 months)						\$ 0.00	\$ 0.00
Terminal disclaimer enclosed, add \$ 110.00						\$ 0.00	\$ 0.00
<input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$770.00)						\$ 0.00	\$ 0.00
<input type="checkbox"/> Please enter the previously unentered , filed							
<input type="checkbox"/> Submission attached							
						Subtotal	\$ 0.00
If "small entity," then enter half (1/2) of subtotal and subtract <input type="checkbox"/> Applicant claims "small entity" status. <input type="checkbox"/> Statement filed herewith						-\$	\$ 0.00
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)						\$	\$ 0.00
Assignment Recording Fee (\$40.00)						\$	\$ 0.00
Other:							\$ 0.00
					TOTAL FEE ENCLOSED	\$	\$ 0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Confirmation No. 4825

SCHNEIDER et al

Atty. Ref.: 620-190

Serial No. 10/088,677

Group:

Filed: May 31, 2002

Examiner:

For: USE OF REPLICATION-DEFICIENT ADENOVIRAL
VECTOR TO BOOST CD8+T CELL IMMUNE RESPONSE
TO ANTIGEN

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

March 22, 2004

Sir:

INFORMATION DISCLOSURE STATEMENT

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C

2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C

2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00

3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each
identified document and a translation or a concise explanation of
each non-English language document (such as a Search Report) is

enclosed herewith.

This paper is submitted in accordance with:

- 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
 - a) The required Statement made in item 8 below; or
 - b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
 - a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
 - b) The required Statement is stated in item 8 below.
- 8. Statement under 37 CFR 1.97(e)
 - a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
 - b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

SCHNEIDER et al
Serial No. 10/088,677
March 22, 2004

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO.	SERIAL NO.
		620-190	10/088,677
		APPLICANT	
		SCHNEIDER et al	
		FILING DATE	GROUP

(Use several sheets if necessary)

MAR 22 2004
PATENT & TRADEMARK OFFICE

(Use several sheets if necessary)

FILING DATE

SERIAL NO.

10/088,677

SCHNEIDER et al.

FILING DATE

GROUP

May 31, 2002

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

Rothel et al, "Sequential nucleic acid and recombinant adenovirus vaccination induces host-protective immune responses against *Taenia ovis* infection in sheep", Parasite Immunology 19:221-227 (1997)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)